ReviewAbdominal radiology (New York)2026
Hyperintense liver lesions on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: clinical insights and significance.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatic Vascular Involvement in Adenosine Deaminase 2 Deficiency (DADA2): Case Reports and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic enhanced CT for detecting occult recurrence after curative ablation of hepatocellular carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatobiliary (HB)-specific magnetic resonance imaging (MRI) contrast agents, particularly gadoxetic acid, are being increasingly utilized for liver imaging, with well-established clinical utility. The most distinctive feature of gadoxetic acid is HB phase imaging performed 20 min after administration. In clinical practice, most focal liver lesions lack gadoxetic acid uptake and appear hypointense against the background of normally enhancing liver parenchyma owing to the absence of hepatocyte function within the tumor tissue. Less commonly, various liver lesions show hyperintensity on HB phase imaging, which is a characteristic diagnostic feature. Hyperintense lesions in the HB phase are crucial diagnostic elements and imaging biomarkers. Hyperintense hepatocellular carcinoma (HCC) demonstrates lower malignancy and a generally good prognosis, but exhibits poorer response to immunotherapies, including anti-programmed cell death inhibitors. Heterogeneously hyperintense HCCs show poor treatment outcomes. Hepatocellular adenomas with β-catenin mutation exhibit HB phase hyperintensity with signal-intensity patterns capable of discriminating malignant transformation potentials based on exon 3 mutation. Focal nodular hyperplasia (FNH) and FNH-like lesions show HB phase hyperintensities with various signal-intensity patterns, significantly reducing unnecessary biopsies for diagnosis. Nodular regenerative hyperplasia and regenerative and multiacinar regenerative nodules also present hyperintensity or ring-like hyperintensity in the HB phase but no enhancement in the arterial phase. Cloud enhancement in intrahepatic cholangiocarcinoma serves as both a key differential diagnostic feature and a poor prognostic indicator. Liver metastases from colorectal, breast, and pancreatic adenocarcinomas occasionally contain mildly hyperintense areas that may correlate with a poor prognosis or lower chemotherapy response. Peritumoral hyperintensity can be identified in hypervascular lesions and relatively large tumors; however, its clinical significance has not yet been established. Understanding hyperintensity patterns in the HB phase aids in accurate imaging diagnosis and offers valuable prognostic and therapeutic biomarker information. This review explores the clinical significance, diagnostic implications, and prognostic value of hyperintense lesions on gadoxetic acid-enhanced MRI.
Indexed as
Identifiers
40824538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.